Ticker Details
iBio, Inc. iBio Inc is a biotechnology company. It is engaged in commercializing its proprietary platform technologies, iBioLaunch for vaccines and therapeutic proteins & iBioModulator for vaccine enhancement and developing select product candidates.
IPO Date:	January 4, 2011
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$82.21M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.08 | 5.61%
Avg Daily Range (30 D):	$0.09 | 4.02%
Avg Daily Range (90 D):	$0.11 | 6.23%

Institutional Daily Volume
Avg Daily Volume:	.33M
Avg Daily Volume (30 D):	1.51M
Avg Daily Volume (90 D):	5.72M

Trade Size
Avg Trade Size (Sh.):	59
Avg Trade Size (Sh.) (30 D):	210
Avg Trade Size (Sh.) (90 D):	307

Institutional Trades
Total Institutional Trades:	127
Avg Institutional Trade:	$1.44M
Avg Institutional Trade (30 D):	$.6M
Avg Institutional Trade (90 D):	$.71M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.69M
Avg Closing Trade (30 D):	$.52M
Avg Closing Trade (90 D):	$.52M
Avg Closing Volume:	14.99K

News

Jan 9, 2026 @ 12:00 PM iBio Announces $26 Million Private Placement Source: Ibio, Inc.

Oct 23, 2025 @ 11:00 AM iBio to Participate in the Guggenheim 2nd Annual H... Source: Ibio, Inc.

Jun 24, 2025 @ 11:00 AM iBio and AstralBio Unveil Obesity Program with Nov... Source: N/A

Jan 2, 2025 @ 12:00 PM iBio Expands Cardiometabolic and Obesity Program w... Source: N/A

Oct 14, 2024 @ 2:58 PM Biopharmaceuticals Contract Manufacturing Industry... Source: Researchandmarkets.Com

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1	$-.09	$-.11
Diluted EPS	$-1	$-.09	$-.11
Revenue	$.3M	$M	$.1M
Gross Profit
Net Income / Loss	$-24.74M	$-8.99M	$-5.72M
Operating Income / Loss	$-25.47M	$-9.45M	$-5.95M
Cost of Revenue
Net Cash Flow	$21.66M	$.56M	$19.55M
PE Ratio

Splits
Nov 29, 2023	1:20
Oct 10, 2022	1:25
Jun 11, 2018	1:10